Rapid genotypic antibiotic susceptibility test using CRISPR-Cas12a for urinary tract infection

Analyst. 2020 Aug 7;145(15):5226-5231. doi: 10.1039/d0an00947d. Epub 2020 Jun 29.

Abstract

The current clinical protocol to conduct a bacterial antibiotic susceptibility test (AST) requires at least 18 hours, and cannot be accomplished during a single visit for patients. Here, a new method based on the technique of CRISPR-Cas12a is utilized to accomplish a bacterial genotypic AST within one hour with good accuracy. Two amplification approaches are employed and compared: (1) enriching the bacterial concentration by culturing in growth media; and (2) amplifying target DNA from raw samples by recombinase polymerase amplification (RPA). The results show that CRISPR combined with RPA can rapidly and accurately provide a bacterial genotypic AST of urine samples with urinary tract infections for precise antibiotic treatment. As such, this technology could open a new class of rapid bacterial genotypic AST for various infectious diseases.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteria / genetics
  • CRISPR-Cas Systems / genetics
  • Clustered Regularly Interspaced Short Palindromic Repeats*
  • Humans
  • Urinary Tract Infections* / diagnosis
  • Urinary Tract Infections* / drug therapy

Substances

  • Anti-Bacterial Agents